Latest News
GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study
8 July 2026 - Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collab...
Helix partners with AstraZeneca to support genomic research for drug discovery and development
8 July 2026 - Enterprise genomics company Helix announced on Tuesday a multi-year relationship with biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN).Under this agreement AstraZeneca will gain access to Helix's continuousl...
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
8 July 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Tuesday the initiation of the Phase III clinical trial for Rentosertib, its potentially first-in-class oral small-molecule inhibitor targeting TNIK for the ...
Invictus Pharmacy and Mullan Pharmaceutical partner to expand patient access to Ganirelix Acetate Injection
8 July 2026 - Invictus Pharmacy, a pharmacy platform managed by Invictus Ventures Inc, and Mullan Pharmaceutical Inc, a pharmaceutical company focused on expanding access to FDA-approved medications through high-capacity manufacturing partnerships an...
Vanda Pharmaceuticals' investigational therapy for Charcot-Marie-Tooth disease type 2S granted FDA Rare Pediatric Disease Designation
8 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oli...